Health in All Policies: Gesundheit als integrales Thema von Stadtplanung und -entwicklung

"Health in All Policies" ist eine Strategie der WHO, die besagt, dass Prävention, Gesundheitsförderung und gesundheitliche Versorgung nicht allein Aufgaben des Gesundheitssektors sind, sondern in allen Themenfeldern öffentlichen Handelns verfolgt werden sollten. In diesem Beitrag werden sowohl die Entwicklung als auch Ziele und Inhalte der Strategie anhand von internationalen Konferenzergebnissen dargestellt, die zudem einen Bezug zu vergleichbaren Konferenzen zur Stadtentwicklung erlauben. Internationale Erfahrungen zur Anwendung der Strategie im Themenfeld der Stadtplanung und -entwicklung aus Europa, den USA und Australien werden vorgestellt. Basierend hierauf werden zusammenfassend Chancen und Herausforderungen des Ansatzes diskutiert.The WHO's "Health in All Policies" strategy regards prevention, health promotion and care as a joint task for all public sectors. This is grounded in a broad understanding of human health. Focusing on the results of international conferences, this paper presents the goals and substance of this strategy as well as experience gained with the strategy in urban planning and development in Europe, the USA and Australia. The paper closes with concluding remarks on opportunities and challenges for "Health in All Policies" as a strategy

Gesundheit und nachhaltige Stadtentwicklung im Spannungsfeld: Analysen, Strategien & Praxis : Dokumentation der 7. Konferenz „Stadt der Zukunft – Gesunde, nachhaltige Metropolen“ am 18. November 2021

Fehr R, Gatting S, Ritzinger S, Hornberg C, eds. Gesundheit und nachhaltige Stadtentwicklung im Spannungsfeld: Analysen, Strategien & Praxis : Dokumentation der 7. Konferenz „Stadt der Zukunft – Gesunde, nachhaltige Metropolen“ am 18. November 2021. Bielefeld: BieColl - Bielefeld eCollections; 2022.Am 18. November 2021 wurde die 7.Konferenz der Reihe „Stadt der Zukunft –Gesunde, nachhaltige Metropolen“ unter dem Titel „Gesundheit und nachhaltige Stadtentwicklung im Spannungsfeld: Analysen, Strategien & Praxis“ im Rahmen der zweitägigen Tandemveran-staltung„Nachhaltige StadtGesundheit“ (17./18.11.2021) als Online-Veranstaltung ausgerich-tet. Die vorliegende Dokumentation beschreibt Kontext, Vorbereitung, Durchführung und In-halte dieser Konferenz sowie ausgewählte Ergebnisse.On 18thNovember 2021, the 7thconference of the series "City of the Future –Healthy, Sustainable Metropolises" took place as online event under the title "Health and Sustainable Urban Development in the Area of Conflict: Analyses, Strategies & Practice", as part of the two-day tandem event "Sustainable UrbanHealth" (17./18.11.2021). This documentation covers the context, preparation, implementation and contents of this conference, as well as selected results

Septicemia Caused by Tick-borne Bacterial Pathogen Candidatus Neoehrlichia mikurensis

We have repeatedly detected Candidatus Neoehrlichia mikurensis, a bacterium first described in Rattus norvegicus rats and Ixodes ovatus ticks in Japan in 2004 in the blood of a 61-year-old man with signs of septicemia by 16S rRNA and groEL gene PCR. After 6 weeks of therapy with doxycycline and rifampin, the patient recovered

Assessment of health risks of policies

The assessment of health risks of policies is an inevitable, although challenging prerequisite for the inclusion of health considerations in political decision making. The aim of our project was to develop a so far missing methodological guide for the assessment of the complex impact structure of policies. The guide was developed in a consensual way based on experiences gathered during the assessment of specific national policies selected by the partners of an EU project. Methodological considerations were discussed and summarized in workshops and pilot tested on the EU Health Strategy for finalization. The combined tool, which includes a textual guidance and a checklist, follows the top-down approach, that is, it guides the analysis of causal chains from the policy through related health determinants and risk factors to health outcomes. The tool discusses the most important practical issues of assessment by impact level. It emphasises the transparent identification and prioritisation of factors, the consideration of the feasibility of exposure and outcome assessmentwith special focus on quantification. The developed guide provides useful methodological instructions for the comprehensive assessment of health risks of policies that can be effectively used in the health impact assessment of policy proposals.

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

This translational study aimed at gaining insight into the effects of lenalidomide in acute myeloid leukemia (AML). Forty-one AML patients aged 66 or older of the Swiss cohort of the HOVON-103 AML/SAKK30/10 study were included. After randomization, they received standard induction chemotherapy with or without lenalidomide. Bone marrow biopsies at diagnosis and before the 2nd induction cycle were obtained to assess the therapeutic impact on leukemic blasts and microenvironment. Increased bone marrow angiogenesis, as assessed by microvessel density (MVD), was found at AML diagnosis and differed significantly between the WHO categories. Morphological analysis revealed a higher initial MVD in AML with myelodysplasia-related changes (AML-MRC) and a more substantial decrease of microvascularization after lenalidomide exposure. A slight increase of T-bet-positive TH1-equivalents was identifiable under lenalidomide. In the subgroup of patients with AML-MRC, the progression-free survival differed between the two treatment regimens, showing a potential but not significant benefit of lenalidomide. We found no correlation between the cereblon genotype (the target of lenalidomide) and treatment response or prognosis. In conclusion, addition of lenalidomide may be beneficial to elderly patients suffering from AML-MRC, where it leads to a reduction of microvascularization and, probably, to an intensified specific T cell-driven anti-leukemic response

Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

Background. Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)-naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven. Methods. MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters. Results. Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P < .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1-infected patients (8.2% vs 2.5%; P = .004). Conclusions. Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin—transmission vs sporadic appearance—of these variants determines their impact on ART needs to be further explore